Silexion Therapeutics Corp (SLXN)

$3.44 +0.07 (2.08%)
Market Cap 10.76M
Revenue (ttm) 0.00
Net Income (ttm) -16.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 26.58
Volume 35,600
Avg Vol 590,258
Day's Range N/A - N/A
Shares Out 3.13M
Stochastic %K 27%
Beta -0.07
Analysts Strong Sell
Price Target $24.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel
EZ_Money11
EZ_Money11 Oct. 14 at 11:18 AM
$SLXN Slap the ask get it moving! Over 5k shares I’m waiting for $5+
0 · Reply
ZacksResearch
ZacksResearch Oct. 10 at 2:00 PM
$SLXN down 87% YTD — can the biotech bounce back? ⛹️‍♂️ Earlier this year, the company executed a 1-for-15 reverse stock split to regain Nasdaq compliance ⚖️ — a key move to stay in the game. It also partnered with Catalent for formulation development and clinical manufacturing of its next-gen siRNA candidate 💊, SIL-204, which targets locally advanced pancreatic cancer and is on track to enter phase II/III studies by the first half of 2026. See the upside Wall Street expects 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-15483&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_15483
0 · Reply
Robotai
Robotai Oct. 10 at 12:30 AM
$SLXN
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 8:44 PM
Keep a close watch on CMCT! $BDRX $NAAS $SLXN $AIHS !!
0 · Reply
Trader1141
Trader1141 Oct. 8 at 10:01 AM
$XBIO $SPRB $SLRX $SLXN Low float with recent news that never ran on is $SLXN … waiting ⏳
1 · Reply
SYC80
SYC80 Oct. 7 at 8:33 AM
$SLXN waking up 😏
0 · Reply
athebeast
athebeast Oct. 6 at 2:33 PM
$ADTX Same business with $SLXN that's why I just short them
0 · Reply
BullsGame
BullsGame Oct. 2 at 3:39 PM
$SLXN Slow but steady
2 · Reply
DiMaMar
DiMaMar Oct. 1 at 5:15 PM
$SLXN https://finance.yahoo.com/news/silexion-therapeutics-announces-positive-human-124000744.html
0 · Reply
debbiekatz
debbiekatz Oct. 1 at 5:07 PM
$SLXN at 3.72. keep swinging. posted here at 3.36
0 · Reply
Latest News on SLXN
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 30, 2025, 8:40 AM EDT - 25 days ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 25, 2025, 8:45 AM EDT - 4 weeks ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 1:26 PM EDT - 6 weeks ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 9:17 AM EDT - 6 weeks ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 11, 2025, 7:00 AM EDT - 6 weeks ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 4, 2025, 9:25 AM EDT - 7 weeks ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:45 AM EDT - 7 weeks ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 2 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 3 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 3 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 3 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 3 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 5 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 5 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 5 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 6 months ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 7 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 7 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 7 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 7 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 12:05 PM EST - 8 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 8 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 8 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 8 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 9 months ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 9 months ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 9 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 12:08 PM EST - 10 months ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 10 months ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jan 16, 2025, 8:51 AM EST - 10 months ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 10 months ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 10 months ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 10 months ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 11 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

EZ_Money11
EZ_Money11 Oct. 14 at 11:18 AM
$SLXN Slap the ask get it moving! Over 5k shares I’m waiting for $5+
0 · Reply
ZacksResearch
ZacksResearch Oct. 10 at 2:00 PM
$SLXN down 87% YTD — can the biotech bounce back? ⛹️‍♂️ Earlier this year, the company executed a 1-for-15 reverse stock split to regain Nasdaq compliance ⚖️ — a key move to stay in the game. It also partnered with Catalent for formulation development and clinical manufacturing of its next-gen siRNA candidate 💊, SIL-204, which targets locally advanced pancreatic cancer and is on track to enter phase II/III studies by the first half of 2026. See the upside Wall Street expects 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-15483&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_15483
0 · Reply
Robotai
Robotai Oct. 10 at 12:30 AM
$SLXN
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 8:44 PM
Keep a close watch on CMCT! $BDRX $NAAS $SLXN $AIHS !!
0 · Reply
Trader1141
Trader1141 Oct. 8 at 10:01 AM
$XBIO $SPRB $SLRX $SLXN Low float with recent news that never ran on is $SLXN … waiting ⏳
1 · Reply
SYC80
SYC80 Oct. 7 at 8:33 AM
$SLXN waking up 😏
0 · Reply
athebeast
athebeast Oct. 6 at 2:33 PM
$ADTX Same business with $SLXN that's why I just short them
0 · Reply
BullsGame
BullsGame Oct. 2 at 3:39 PM
$SLXN Slow but steady
2 · Reply
DiMaMar
DiMaMar Oct. 1 at 5:15 PM
$SLXN https://finance.yahoo.com/news/silexion-therapeutics-announces-positive-human-124000744.html
0 · Reply
debbiekatz
debbiekatz Oct. 1 at 5:07 PM
$SLXN at 3.72. keep swinging. posted here at 3.36
0 · Reply
zsc
zsc Oct. 1 at 4:13 PM
$SLXN - https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-silexion-therapeutics-promising-preclinical-data-and-strategic-trial-plans-boost-investment-appeal-ratings?mod=mw_quote_news
0 · Reply
StockRedBaron
StockRedBaron Oct. 1 at 11:49 AM
$SLXN Just emailed out by Parisi: Silexion Therapeutics Corp (SLXN - $3.40 - Buy - $24.00 PT): Additional Pre-Clinical Data for SIL-204 Finds Pan-KRAS Activity Across Multiple Cancer Types & KRAS Mutations (Analyst: Naz Rahman, CFA)
0 · Reply
EZ_Money11
EZ_Money11 Oct. 1 at 2:48 AM
$SLXN $6.70’s fill the gap! 🎯
0 · Reply
debbiekatz
debbiekatz Sep. 30 at 9:13 PM
nice pop for $SLXN today hitting 5.2 earlier- last posted for team at 3.57 on 9/23 for 46% gain. it's at 3.36 now.
1 · Reply
DekmarTrades
DekmarTrades Sep. 30 at 8:13 PM
I LOVE THIS TIME OF THE YEAR! I trade multiple times throughout the day and now I am on a 7 day WINNING STREAK! Volume is high, news is hot, and there are so many trades early in the morning! $NUWE $SLXN $WOLF
0 · Reply
TheBigSmallBigShort
TheBigSmallBigShort Sep. 30 at 3:52 PM
$SLXN I'm out, fck this
0 · Reply
TheBigSmallBigShort
TheBigSmallBigShort Sep. 30 at 3:17 PM
$SLXN come on go up
0 · Reply
Unalloyed
Unalloyed Sep. 30 at 2:54 PM
$SLXN
0 · Reply
orgeneralosa
orgeneralosa Sep. 30 at 2:01 PM
$SLXN look at the news look at the manipulation
0 · Reply
Trader1141
Trader1141 Sep. 30 at 1:59 PM
$QMMM Manupulation??? Rela manipulation at $SLXN
0 · Reply
Tom678
Tom678 Sep. 30 at 1:47 PM
$SLXN agree
0 · Reply
Robotai
Robotai Sep. 30 at 1:47 PM
$SLXN 📈 Follow & Subscribe Swing Trading Forecast: $SLXN 📍 Current Price: $3.42 🔍 Swing Patterns: High Volume Bearish Move, High Volume Bearish Move, MACD Bearish Crossover 📊 Swing Market Structure: • Trend Regime: Range Bound • Direction: Bearish (81.2% confidence) • Timeframe: 1-3 days 🎯 Bearish Swing Targets: • Conservative: $2.99 (-9.65%) • Primary Target: $2.78 (-16.08%) • Aggressive: $2.35 (-28.94%) • Holding Period: 1-3 days 📊 Technical Indicators: • ADX (Trend Strength): 17.9 • ATR (Volatility): $0.07 • RSI: 38.7 • MACD: Bearish 🧠 Historical Pattern Match: • Similar to: 2025-09-12 • Matched patterns: MACD Bearish Crossover, Perfect Bearish Swing Alignment 📈 Swing Signal Strength: 81.2% | Historical Patterns: 5
0 · Reply